In the last 10 years, The FARA Energy Ball has.

- Funded >$13 Million in Drug Discovery and Development and Clinical Research; including five clinical trials 2013-2018 (2 of the funded trials at USF)

- Expanded the research capacity of the Collaborative Clinical Research Network (CCRN) in FA:
  - >1000 individuals with FA enrolled in clinical research
  - Biobank with DNA, RNA, serum, and plasma samples available for collaborative research with pharmaceutical companies

- Raised unparalleled awareness of FA within the Tampa Bay community and beyond

2019 Initiatives- FARA needs to raise >$8 million

- Advance drug candidates in a deep and diverse treatment pipeline
- Develop the genetic based research findings to therapeutic agents for people living with FA
- Grow the scientific community to bring new ideas and expertise to advance the field
- Support a worldwide network of clinical research and care centers for FA
- Reduce mortality caused by severe cardiac abnormalities
- Facilitate an International Collaborative FA Biomarker Consortium to accelerate therapy development for FA
- Restructure the FARA Patient Registry to be a worldwide registry and fully enroll all open clinical trials

Acting alone there is very little any of us can accomplish. Acting together there is very little we will not accomplish.

-Ron Bartek, FARA Founder and President
In the last 20 years, FARA has . . .

- Funded >$46 Million in FA Drug Discovery and Development and Clinical Research
- Leveraged an additional research dollars from co-funding partners
- Helped individuals with FA participate in clinical research and get improved medical care
- Educated the medical and patient communities regarding FA and research advances
- Raised awareness of FA so that those diagnosed are no longer isolated

For a complete list of funded projects, please visit our website at: http://www.curefa.org/grants

Because of supporters like you . . .

FARA has been able to dramatically increase the number of potential treatments for FA in just a few years (see graph below). To learn more about the progress of these additional approaches, please visit our website at: http://www.curefa.org/pipeline

Breakthroughs and Milestones . . .

- 1996 - The disease-causing gene mutation was identified
- 1998 - FARA was founded
- 2001 - The first animal models of FA were created
- 2006 - Number of researchers working in FA doubled and FARA Patient Registry was launched
- 2007 - International Collaborative Clinical Research Network for FA was established
- 2009-2011 - Number of new drug candidates and pharmaceutical companies interested in FA doubled
- 2012 - Gene therapy shown to reverse FA cardiac disease in a mouse model
- 2013 - 5 new clinical trials initiated and 3 new candidates added to treatment pipeline
- 2014 - FARA established Penn Medicine / CHOP Friedreich’s Ataxia Center of Excellence; 3 new pharmaceutical companies formed to advance gene therapy in FA
- 2015-2017 - FARA implemented collaborative FA Biomarker initiative with industry & academic partners
- 2018 – Gene therapy shown to reverse FA neurological disease in mouse model
  - Completed enrollment for a phase II & a phase III trial with >175 participants

Acting alone there is very little any of us can accomplish
Acting together there is very little we will not accomplish.

-Ron Bartek, FARA Founder and President